Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEN vs Infliximab in Pediatric Crohn's Disease
NCT04530877Phase 4Withdrawn
- Sponsor
- Children's Hospital of Fudan University
- Start
- Oct 2022
- Primary completion
- Sep 2024
01
Overview
Phase 4, randomised, open-label trial in Crohn's disease (2 arms), sponsored by Children's Hospital of Fudan University. Primary endpoint: Number of patients who reach mucosal healing at 14 weeks. Planned start Oct 2022; status: withdrawn.
02
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04530877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530877.